UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 30, 2005
VALEANT PHARMACEUTICALS INTERNATIONAL
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation)
|
|
1-11397
(Commission
File Number)
|
|
33-0628076
(I.R.S. Employer
Identification No.) |
|
|
|
3300 Hyland Avenue
Costa Mesa, California
(Address of principal executive offices)
|
|
92626
(Zip Code) |
(714) 545-0100
(Registrants telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement
On December 29, 2005 and effective as of January 1, 2006, Valeant Pharmaceuticals
International (the Company) entered into an agreement (the Agreement) with Robert OLeary
providing for the terms pursuant to which Mr. OLeary, the Executive Chairman of the Board of
Directors of the Company, will continue to serve as non-executive Chairman of the Board of
Directors.
The initial term of the Agreement is from January 1, 2006 until the election of the Chairman
of the Board of Directors immediately following the annual stockholders meeting in May, 2006 (the
Initial Term). The term of the Agreement shall be automatically extended to each successive
period as to which the Board of Directors of the Company elects Mr. OLeary as Chairman and Mr.
OLeary agrees to serve as Chairman.
The Agreement provides that, for the Initial Term, on or before January 5, 2006, Mr. OLeary
shall receive a pro-rated retainer of $12,500 and beginning with meetings occurring on or after
January 1, 2006, shall be paid meeting and other fees consistent with the fee schedule generally
applicable, as adopted from time to time by the Board of Directors of the Company. For any
subsequent terms, Mr. OLeary shall receive the retainer payable to all directors, paid on the
schedule generally applicable to directors. In addition, the Agreement provides that upon signing
of the Agreement, in consideration of his service for the Initial Term, the Company shall grant Mr.
OLeary 5,000 Restricted Stock Units upon the terms and conditions generally applicable to such
grants to members of the Board of Directors of the Company. For each subsequent term (each such
term beginning upon Mr. OLearys election as Chairman at the Board of Directors meeting
immediately following the annual stockholders meeting, as provided in the bylaws of the Company) as
non-executive Chairman, the Company shall grant Mr. OLeary a number of restricted stock units
equal in value to $240,000, upon the terms and conditions generally applicable to such grants to
members of the Board of Directors of the Company.
The Agreement further provides that, for as long as Mr. OLeary provides services to the
Company whether as an employee, non-employee director, or consultant, to the extent provided in the
applicable stock plans and stock option agreements, stock options currently held by him shall
continue to vest in accordance with the existing stock agreement terms and conditions, including
acceleration in the event of a change in control (as such term defined in the Agreement). The
Agreement also includes additional terms relating to the exercisability of Mr. OLearys stock
options in the event of a change in control.
If it is determined that Mr. OLeary is entitled to payments and/or benefits which would
constitute parachute payments within the meaning of section 280G(b)(2) of the Internal Revenue
Code (the Code) and, with respect to such excess parachute payment, would be subject to the
excise tax imposed by Section 4999 of the Code and/or any interest or penalties with respect to
such excise tax (such excise tax, together with any such interest and penalties, are hereinafter
collectively referred to as the Excise Tax), then Mr. OLeary will be entitled to receive an
additional amount (the Gross-Up Payment) such that after payment by Mr. OLeary of all taxes
(including any interest or penalties imposed with respect to such taxes), including, without
limitation, any income taxes (and any interest and penalties imposed with respect thereto) and any
excise tax imposed by Section 4999 of the Code (and any interest and penalties imposed with respect
thereto) upon the Gross-Up Payment, Mr. OLeary retains an amount of the Gross-Up Payment equal to
the Excise Tax imposed upon the excess parachute payment; provided, however, that Mr. OLeary shall
not be entitled to receive a Gross-Up Payment with respect to any excise tax other than the initial
application of the Excise Tax (although the amount, if any, of excise tax due with respect to the
Gross-Up Payment shall be taken into account in determining whether, on an
2
after-tax basis, the Gross-Up Payment is sufficient to cover the initial application of the Excise
Tax). No equity compensation rights or cash compensation increases granted on or after November
17, 2004 will be eligible for a Gross-Up Payment. To the extent that Mr. OLeary is subject to the
Excise Tax when taking into account post-November 16 increases, but would not be subject to the
Excise Tax if such increases were not taken into account, he will be entitled to a prorated
Gross-Up Payment based on a ratio of pre-November 17 compensation compared to all parachute
payments.
The foregoing summary of the Agreement is qualified in its entirety by the actual Agreement
attached hereto as Exhibit 10.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
|
|
|
Exhibit No. |
|
Description |
10.1
|
|
Agreement, dated December 30, 2005, effective as of January 1, 2006, between the Company and Robert OLeary. |
3